Cite
HARVARD Citation
Weisel, K. et al. (2020). Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leukemia & lymphoma. 61 (8), pp. 1850-1859. [Online].